Search results for " fenofibrate"

showing 2 items of 2 documents

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidaemia: a randomized pilot tria

2013

Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open-label, blinded end point (PROBE) study (ClinicalTrials.gov identifier: NCT01010516). Patients (n = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) or to add-on-statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low-density lipoprotein (LDL) …

C-reactive protein fenofibrate lipoprotein-associated phospholipase A2 nicotinic acid rosuvastatin small dense low-density lipoprotein cholesterol.
researchProduct

Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype

2013

Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. Methods and Results Urinary 8‐iso‐PGF 2α and 11‐dehydro‐TXB 2 , in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/ dL , and in 47 CHD patients with HDL &gt…

MaleSettore MED/09 - Medicina InternaCoronary DiseaseDinoprostmedicine.disease_causeLipid peroxidationchemistry.chemical_compoundFenofibrateHDL cholesterolRisk FactorsCoronary Heart Diseaseoxidative stressMyocardial infarctionOriginal ResearchHypolipidemic AgentsplateletHypoalphalipoproteinemiasFenofibrateMiddle AgedAged; Arachidonic Acids; Case-Control Studies; Cholesterol HDL; Coronary Disease; Cross-Sectional Studies; Dinoprost; Exercise; Exercise Therapy; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Phenotype; Platelet Activation; Risk Factors; Sedentary Lifestyle; Thromboxane B2; Cardiology and Cardiovascular MedicineExercise TherapyCholesterolPhenotypeSedentary LifestyleFemalelipids (amino acids peptides and proteins)exercise HDL cholesterol oxidative stress plateletCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyHDLArachidonic AcidsDiabetes mellitusInternal medicinemedicineHumansPlatelet activationExerciseAgedCreatininebusiness.industryCholesterol HDLCase-control studyPlatelet Activationmedicine.diseaseThromboxane B2Cross-Sectional StudiesEndocrinologychemistryCase-Control StudiesLipid PeroxidationSedentary BehaviorbusinessOxidative stressLipoproteinEuropean Heart Journal
researchProduct